Theodora Mistras - 09 Jul 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: CVP, Chief Financial Officer
Issuer ticker: EW
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 17:11:14 UTC
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Theodora Mistras filed Form 4 for Edwards Lifesciences Corp (EW) on 10 Jul 2026.

Key facts

This page summarizes Theodora Mistras's Form 4 filing for Edwards Lifesciences Corp (EW).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Jul 2026, 17:11.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002013495 Primary reporting owner

Mistras Theodora

Relationship: CVP, Chief Financial Officer
Address: ONE EDWARDS WAY, IRVINE
Signature: Linda J. Park, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Award

Transaction value
Shares: +87,595
Change %
Price: $0.000000^*
Shares after: 87,595
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

EW transaction

Common Stock

Award

Transaction value
Shares: +12,325
Change %: +14%
Price: $0.000000^*
Shares after: 99,920
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Award

Transaction value
Shares: +61,800
Change %
Price: $0.000000^*
Shares after: 61,800
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,800
Exercise price: $91.33
Footnotes: F3

EW transaction Derivative

Performance Rights

Award

Transaction value
Shares: +12,325
Change %
Price: $0.000000^*
Shares after: 12,325
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,325
Exercise price
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These restricted stock units were granted on July 9, 2026, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest as follows: 43.75% on the first anniversary of May 29, 2026 (the "Start Date"), 50% on the second anniversary of the Start Date, and the remaining 6.25% on the third anniversary of the Start Date.

Footnote F2

These restricted stock units were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F3

These options were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F4

Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on July 9, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.